Shanghai Ruifu Chemical Co., Ltd. is the leading manufacturer and supplier of L-Alaninamide Hydrochloride (H-Ala-NH2·HCl) (CAS: 33208-99-0) with high quality, an intermediate of Safinamide (CAS: 133865-89-1). We can provide worldwide delivery, small and bulk quantities available. If you need L-Alaninamide Hydrochloride, Please contact: alvin@ruifuchem.com
| Chemical Name |
L-Alaninamide Hydrochloride |
| Synonyms |
L-Alaninamide HCl; H-Ala-NH2·HCl; L-Ala-NH2·HCl; (S)-2-Aminopropionamide Hydrochloride; (S)-2-Aminopropionamide HCl; (2S)-2-Aminopropanamide Hydrochloride |
| Stock Status |
In Stock, Production Capacity 100 Tons per Year |
| CAS Number |
33208-99-0 |
| Molecular Formula |
C3H8N2O·HCl |
| Molecular Weight |
124.57 g/mol |
| Melting Point |
200.0~220.0℃ |
| Sensitive |
Air Sensitive |
| Solubility |
Soluble in Methanol |
| Storage Temp. |
Sealed in Dry, Store at Room Temperature |
| COA & MSDS |
Available |
| Classification |
Amino Acids & Derivatives |
| Brand |
Ruifu Chemical |
| Hazard Codes |
C - Corrosive |
WGK Germany |
3 |
| Safety Statements |
24/25 - Avoid contact with skin and eyes. |
HS Code |
2922491990 |
| Items |
Inspection Standards |
Results |
| Appearance |
White to Off-White Powder |
Conforms |
| Infrared Spectrometry |
Conforms to Structure |
Conforms |
| Assay / Analysis Method |
98.0~102.0% |
99.3% |
| Melting Point |
200.0~220.0℃ |
214.0~216.0℃ |
| Specific Rotation [α]20/D |
+9.0° to +13.0°(C=1, CH3OH) |
+12.43° |
| Loss on Drying |
<0.50% |
0.15% |
| Residue on Ignition |
<0.10% |
0.05% |
| Iron (Fe) |
<10ppm |
<10ppm |
| Sulfate (SO4) |
<0.02% |
<0.02% |
| Heavy Metals (Pb) |
<10ppm |
<10ppm |
| Ammonium (NH4) |
<0.08% |
<0.08% |
| Arsenic (As2O3) |
<1ppm |
<1ppm |
| Conclusion |
This Product by Inspection Accords with the Enterprise Standard |
| Main Uses |
Pharmaceutical Intermediates; Safinamide Intermediate |
Package: Fluorinated Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement
Storage Condition: Store in sealed containers at cool, dry and ventilated warehouse away from incompatible substances. Protect from light and moisture.
How to Purchase? Please contact Dr. Alvin Huang: sales@ruifuchem.com or alvin@ruifuchem.com
15 Years Experience? We have more than 15 years of experience in the manufacture and export of a wide range of high quality pharmaceutical intermediates or fine chemicals.
Main Markets? Sell to domestic market, North America, Europe, India, Korea, Japanese, Australia, etc.
Advantages? Superior quality, affordable price, professional services and technical support, fast delivery.
Quality Assurance? Strict quality control system. Professional equipment for analysis include NMR, LC-MS, GC, HPLC, ICP-MS, UV, IR, OR, K.F, ROI, LOD, MP, Clarity, Solubility, Microbial limit test, etc.
Samples? Most products provide free samples for quality evaluation, shipping cost should be paid by customers.
Factory Audit? Factory audit welcome. Please make an appointment in advance.
MOQ? No MOQ. Small order is acceptable.
Delivery Time? If within stock, three days delivery guaranteed.
Transportation? By Express (FedEx, DHL), by Air, by Sea.
Documents? After sales service: COA, MOA, ROS, MSDS, etc. can be provided.
Custom Synthesis? Can provide custom synthesis services to best fit your research needs.
Payment Terms? Proforma invoice will be sent first after confirmation of order, enclosed our bank information. Payment by T/T (Telex Transfer), PayPal, Western Union, etc.
L-Alaninamide Hydrochloride (H-Ala-NH2·HCl) (CAS: 33208-99-0) is used as pharmaceutical intermediates. L-Alaninamide Hydrochloride is used for preparation of novel amide derivatives of steroidal[3,2-c]pyrazole compounds with glucocorticoid activity. L-Alaninamide Hydrochloride is an intermediate of Safinamide (CAS: 133865-89-1) and Safinamide Mesylate (CAS: 202825-46-5). Safinamide is a selective and reversible inhibitor of monoamine oxidase B (MAO-B, IC50=98 nM with greater than 100-fold selectivity over MAO-A. Displays anticonvulsant activity and protects against kainate-induced seizures and hippocampal neurodegeneration in rat models. Reduces overactive glutamatergic signaling via use-dependent sodium channel blockade. A novel therapeutic for Parkinson’s disease with multiple modes of action. Effective as an add-on to dopamine agonist therapy in early Parkinson's. Safinamide methanesulfonate was approved in February 2015 by the EMA for the treatment of mid- to late-stage fluctuating Parkinson’s disease. This approval included use of the drug as an add-on therapy for use with Levodopa, either alone or in combination with other existing therapies for Parkinson’s disease. Safinamide methanesulfonate, an oral α-aminoamide originally discovered by Farmitalia Carlo Erba and later developed by Newron/Zambon, functions as a highly selective and reversible inhibitor of MAO-B, leading to increased levels of dopamine and subsequent improvement in the motor symptoms of Parkinson’s disease, side effects that often result from use of other traditional treatments relying on dopamine replacement therapy.